Guard Therapeutics: First Patient in – Phase Ib
Redeye acknowledges a milestone with the first patient enrolled in the phase I trial with ROSgard in patients undergoing cardiac surgery. The trial will recruit approximately 12 patients and we expect, in line with the company, a readout in late Q2. In parallel, preparations for a phase II trial are ongoing and we expect to get further visibility into the final study protocol once phase Ib data is in place. Our Base case remains at SEK 3 per share.